Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.
about
Developing strategies in the immunotherapy of leukemiasTherapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contactsPreferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignanciesmRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapiesIdentification of novel HLA-B27 ligands derived from polymorphic regions of its own or other class I molecules based on direct generation by 20 S proteasome.TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.Identification of endogenously presented peptides from Chlamydia trachomatis with high homology to human proteins and to a natural self-ligand of HLA-B27.MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsRecognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients.Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetesStudy of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPsIncreased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Tumor-specific shared antigenic peptides recognized by human T cells.Towards patient-specific tumor antigen selection for vaccination.Mechanisms of MHC class I-restricted antigen presentation.HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgeniTherapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of conceptStrategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantationPost-proteasomal antigen processing for major histocompatibility complex class I presentation.The processing of antigens delivered as DNA vaccines.Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs.Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation.Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing TumorsReverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.PRAME expression in hairy cell leukemia.Dendritic cell vaccines for leukemia patients.Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Identification of T-cell epitopes for cancer immunotherapy.Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches.The immunoinformatics of cancer immunotherapy.Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.Update on vaccine development for renal cell cancer.Recognition of human proinsulin leader sequence by class I-restricted T-cells in HLA-A*0201 transgenic mice and in human type 1 diabetes.
P2860
Q26996310-3E0E464A-77AA-4AF5-B365-BD7421E5E9B7Q27313856-0B0429C0-8246-4781-B84A-69917D99C363Q27631018-1F98DA0F-3C1D-4CEB-AE80-2141215BD035Q28190215-6A7CA7B5-497A-4640-BB81-7CD0C58A552EQ28236215-141F3DCD-A0BC-4633-8326-BCBD08C6C23DQ30685469-A08109DB-F223-44A0-ADC0-C7644F2E7B62Q30831500-08F9A433-0123-4BCE-AEF9-D88FDEE70697Q33302499-59F63921-D6F2-4983-A979-EB6561C5BF9AQ33378044-0CB4F547-0493-4C55-8BAC-2779E66E3FFCQ33482103-B1024073-5160-4A95-8711-EE8CA6D8397EQ33806895-D5FE2C91-D7F6-49ED-A3DB-9029B8C3DE2AQ33906726-DDF6918D-D690-4593-B0FF-EE589A98F2A9Q34234705-F40BE3CC-C448-43B9-AB7B-2F46B782E1F3Q34348731-F86D2B38-F907-409C-8207-13514116045BQ34608912-69EA4B3C-DF7B-4D98-8251-9FEEF80A843DQ34935239-DDE7297F-A959-41E5-8896-200C62360E53Q35005926-05644642-638F-4FD4-A4FF-5391FBED199BQ35005960-3CC15221-FD9D-49DD-B63B-C19645311639Q35050403-8DD9C1A3-B591-4B41-AB73-98A1C8200D29Q35122383-6FD3192C-DFDE-443D-902D-0BC8966C14F4Q35193892-B7153F60-0832-46C2-8957-C2F44829FF39Q35588845-9F203953-1381-43FB-B245-BE4FE5A1931CQ35821228-D9FCFCD0-6900-4112-9307-F8879C0C7018Q35826365-102E9EE2-0595-4748-985B-F52C3409A193Q35884710-9B3C22A5-9485-4553-ADE7-5B0254B941DFQ36065876-CD38EEBF-B0CE-421D-9037-CF863334B466Q36095397-37C68CA9-F487-46BB-97CB-EA8E8518A589Q36266433-8831AED9-A837-4FA9-ABD2-4DFEE5BDF4D9Q36308346-C34B5FE4-B7E4-40CE-BCD4-14ED2488404BQ36322371-FAED73F9-6EC8-4B17-9B68-306C50A7811FQ36471831-2808AB7E-E403-4696-979C-A63628CBDA32Q36748859-4050CABE-4BA3-45AD-8717-76B0AC6A6FEFQ36752018-80C05C22-4440-436F-AAC7-98E24BD9CD8AQ36793112-2096BA97-A389-45D9-B568-16EE7A33A92FQ36870592-AB1FA4BC-2F14-47B5-8E19-9474FEDD5094Q36899098-B4646E41-5428-4FF3-B6DA-5778FC9D89A5Q36927645-6AFF3567-7E58-4AD0-9A3F-115D93359504Q36946100-8EF2E5B3-6FED-45F6-AC2C-38B8FD442C37Q36989720-10E6EB42-33E3-424D-9770-53F8C8D7FF16Q37066897-FD485208-77C1-4CB7-8D47-BB96C32D43E4
P2860
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Efficient identification of no ...... e-mediated digestion analysis.
@en
type
label
Efficient identification of no ...... e-mediated digestion analysis.
@en
prefLabel
Efficient identification of no ...... e-mediated digestion analysis.
@en
P2093
P2860
P50
P356
P1476
Efficient identification of no ...... me-mediated digestion analysis
@en
P2093
A M Kloosterman-Joosten
C J Melief
D C Vissers
F Ossendorp
G J ten Bosch
J H Kessler
J Wouter Drijfhout
M G Kester
N J Beekman
R Offringa
P2860
P356
10.1084/JEM.193.1.73
P407
P577
2001-01-01T00:00:00Z